NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

Core Insights - NervGen Pharma Corp. is set to present clinical data from the Phase 1b/2a CONNECT SCI Study, highlighting durable improvements in function, independence, and quality of life for individuals with chronic spinal cord injury [1] - The presentation will take place at the Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium, scheduled for February 15-17, 2026, in Washington, DC [1][2] Company Overview - NervGen Pharma is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic conditions [4] - The company's lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide that has shown durable improvement in function and quality of life in chronic spinal cord injury patients [4] - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the EMA for the treatment of spinal cord injury [4] Event Details - The presentation titled "Emerging Therapies with Challenges and Opportunities for the Future" will include a panel discussion and is scheduled for February 15, 2026, from 4:15-5:00 pm ET [2] - Key participants in the panel include experts from Lifeward and the FDA, indicating a collaborative approach to addressing spinal cord injury [2] Industry Context - Unite2Fight Paralysis is a nonprofit organization aimed at uniting the spinal cord injury community to advocate for research and treatment options [3] - The Annual Science and Advocacy Symposium serves as a central forum for stakeholders in the spinal cord injury community, promoting collaboration among scientists, clinicians, and policymakers [3]